Cargando…
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
Neuroblastoma is the most commonly diagnosed extracranial tumor in the first year of life. Approximately 9% of neuroblastoma patients present germline or somatic aberrations in the gene encoding for anaplastic lymphoma kinase (ALK). This increases in high-risk neuroblastomas, which have a 14% freque...
Autores principales: | Cervantes-Madrid, Diana, Szydzik, Joanna, Lind, Dan Emil, Borenäs, Marcus, Bemark, Mats, Cui, Jean, Palmer, Ruth Helen, Hallberg, Bengt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920469/ https://www.ncbi.nlm.nih.gov/pubmed/31852910 http://dx.doi.org/10.1038/s41598-019-55060-7 |
Ejemplares similares
-
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019) -
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021) -
IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway
por: Guan, Jikui, et al.
Publicado: (2023) -
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
por: Szydzik, Joanna, et al.
Publicado: (2021) -
ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)